Drug Trial Radar · NCT06436742
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Sep 24, 2024
Primary completion
Aug 24, 2027
Study completion Jan 24, 2028
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- May 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenital Myasthenic Syndromes. The study will also assess how ARGX-119 is processed by the body (pharmacokinetics), how the immune system reacts to it (immunogenicity), and how it may improve the way patients feel and function. After the screening period, eligible participants will be randomized in a 4:1 ratio to receive intravenous infusions of ARGX-119 or placebo during the double-blinded treatment period. Participants will then enter the follow-up period. After the follow-up period, participants may enrol in the active-treatment period, where they will receive open-label ARGX-119. The full duration of the study is approximately 38 months.
Conditions
- Congenital Myasthenic Syndrome
- CMS
Interventions
ARGX-119Biological
Intravenous infusion of ARGX-119
PlaceboOther
Intravenous infusion of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of adverse events (AEs)Time frame: Up to week 42
- Change from active-treatment baseline over time for 6MWT distanceTime frame: Up to 72 weeks
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
UC Davis Medical Center
Sacramento, California
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois
Ottawa Hospital Research Institute - Civic Campus
Ottawa, Canada
CHU - Hospital de la Timone
Marseille, France
Group Hospitalier Pitie-Salpetriere
Paris, France
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
Valencia, Spain
Clinical Trials Centre - South Eastern Health and Social Care Trust - The Ulster Hospital
Belfast, United Kingdom
John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.